| Line |
Label |
Object Class |
Period Type |
Balance |
Report ElementName |
| 1 |
100000 - Document - Document and Entity Information |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DocumentDocumentAndEntityInformation |
| 2 |
Implied Table |
Table |
* |
* |
implied:Table |
| 3 |
Document And Entity Information [Abstract] |
Abstract |
|
|
asln:DocumentAndEntityInformationAbstract |
| 4 |
Document Type |
Concept (Submission Type) |
For Period |
|
dei:DocumentType |
| 5 |
Amendment Flag |
Concept (Yes/No) |
For Period |
|
dei:AmendmentFlag |
| 6 |
Document Period End Date |
Concept (Date) |
For Period |
|
dei:DocumentPeriodEndDate |
| 7 |
Document Fiscal Year Focus |
Concept (Year) |
For Period |
|
dei:DocumentFiscalYearFocus |
| 8 |
Document Fiscal Period Focus |
Concept (Fiscal Period) |
For Period |
|
dei:DocumentFiscalPeriodFocus |
| 9 |
Trading Symbol |
Concept (Text/String) |
For Period |
|
dei:TradingSymbol |
| 10 |
Entity Registrant Name |
Concept (Text/String) |
For Period |
|
dei:EntityRegistrantName |
| 11 |
Entity Central Index Key |
Concept (CIK Number) |
For Period |
|
dei:EntityCentralIndexKey |
| 12 |
Current Fiscal Year End Date |
Concept (Month/Day) |
For Period |
|
dei:CurrentFiscalYearEndDate |
| 13 |
Entity Well-known Seasoned Issuer |
Concept (Yes/No) |
For Period |
|
dei:EntityWellKnownSeasonedIssuer |
| 14 |
Entity Current Reporting Status |
Concept (Yes/No) |
For Period |
|
dei:EntityCurrentReportingStatus |
| 15 |
Entity Filer Category |
Concept (Filer Category) |
For Period |
|
dei:EntityFilerCategory |
| 16 |
Entity Emerging Growth Company |
Concept (Yes/No) |
For Period |
|
dei:EntityEmergingGrowthCompany |
| 17 |
Entity Ex Transition Period |
Concept (Yes/No) |
For Period |
|
dei:EntityExTransitionPeriod |
| 18 |
Entity Shell Company |
Concept (Yes/No) |
For Period |
|
dei:EntityShellCompany |
| 19 |
Entity Common Stock, Shares Outstanding |
Concept (Shares) |
As Of |
|
dei:EntityCommonStockSharesOutstanding |
| 20 |
100010 - Statement - Consolidated Balance Sheets |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/StatementConsolidatedBalanceSheets |
| 21 |
Implied Table |
Table |
* |
* |
implied:Table |
| 22 |
Statement Of Financial Position [Abstract] |
Abstract |
|
|
ifrs-full:StatementOfFinancialPositionAbstract |
| 23 |
ASSETS |
Abstract |
|
|
ifrs-full:AssetsAbstract |
| 24 |
CURRENT ASSETS |
Abstract |
|
|
ifrs-full:CurrentAssetsAbstract |
| 25 |
Cash and cash equivalents (Notes 4 and 6) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 26 |
Prepayments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Prepayments |
| 27 |
Total current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 28 |
NON-CURRENT ASSETS |
Abstract |
|
|
ifrs-full:NoncurrentAssetsAbstract |
| 29 |
Financial assets at fair value through profit or loss (Notes 4, 7 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss |
| 30 |
Financial assets at fair value through other comprehensive income (Notes 4, 8 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome |
| 31 |
Property, plant and equipment (Notes 4 and 9) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 32 |
Intangible assets (Notes 4, 5, 10 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 33 |
Refundable deposits |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:LongtermDeposits |
| 34 |
Total non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 35 |
TOTAL ASSETS |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Assets |
| 36 |
LIABILITIES AND EQUITY |
Abstract |
|
|
ifrs-full:EquityAndLiabilitiesAbstract |
| 37 |
CURRENT LIABILITIES |
Abstract |
|
|
ifrs-full:CurrentLiabilitiesAbstract |
| 38 |
Trade payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers |
| 39 |
Other payables (Notes 11 and 19) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherCurrentPayables |
| 40 |
Total current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 41 |
NON-CURRENT LIABILITIES |
Abstract |
|
|
ifrs-full:NoncurrentProvisionsAbstract |
| 42 |
Long-term borrowings (Note 12) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LongtermBorrowings |
| 43 |
Other non-current liabilities (Note 19) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentLiabilities |
| 44 |
Total non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 45 |
Total liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 46 |
EQUITY (Note 14) |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 47 |
Ordinary shares |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 48 |
Capital surplus |
Concept (Monetary) |
As Of |
Credit |
asln:CapitalSurplus |
| 49 |
Accumulated deficits |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 50 |
Total equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 51 |
TOTAL LIABILITIES AND EQUITY |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAndLiabilities |
| 52 |
100020 - Statement - Consolidated Statement of Comprehensive Loss |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/StatementConsolidatedStatementOfComprehensiveLoss |
| 53 |
Implied Table |
Table |
* |
* |
implied:Table |
| 54 |
Statement Of Comprehensive Income [Abstract] |
Abstract |
|
|
ifrs-full:StatementOfComprehensiveIncomeAbstract |
| 55 |
NET REVENUE (Notes 3, 4, 15 and 24) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromContractsWithCustomers |
| 56 |
COST OF REVENUE (Note 15) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CostOfSales |
| 57 |
OPERATING EXPENSES (Notes 13, 16 and 19) |
Abstract |
|
|
ifrs-full:ExpenseByNatureAbstract |
| 58 |
General and administrative expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GeneralAndAdministrativeExpense |
| 59 |
Research and development expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 60 |
LOSS FROM OPERATIONS |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossFromOperatingActivities |
| 61 |
NON-OPERATING INCOME AND EXPENSES |
Abstract |
|
|
asln:NonOperatingIncomeAndExpensesAbstract |
| 62 |
Interest income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromInterest |
| 63 |
Other income (Note 15) |
Concept (Monetary) |
For Period |
Credit |
us-gaap:OtherIncome |
| 64 |
Other gains and losses (Note 16) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherGainsLosses |
| 65 |
Finance costs (Notes 4 and 16) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 66 |
Total non-operating income and expenses |
Concept (Monetary) |
For Period |
Credit |
asln:NetNonOperatingIncomeExpense |
| 67 |
LOSS BEFORE INCOME TAX |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 68 |
INCOME TAX EXPENSE (Notes 4, 5 and 17) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 69 |
NET LOSS FOR THE YEAR |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 70 |
TOTAL COMPREHENSIVE LOSS FOR THE YEAR |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 71 |
LOSS PER SHARE (Note 18) |
Abstract |
|
|
ifrs-full:BasicEarningsPerShareAbstract |
| 72 |
Basic and diluted |
Concept (Share) |
For Period |
|
ifrs-full:BasicAndDilutedEarningsLossPerShare |
| 73 |
100030 - Statement - Consolidated Statement of Changes in Equity |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/StatementConsolidatedStatementOfChangesInEquity |
| 74 |
Statement Of Changes In Equity [Table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 75 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 76 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 77 |
Ordinary Shares |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 78 |
Capital Surplus |
Member |
|
|
ifrs-full:SharePremiumMember |
| 79 |
Accumulated Deficits |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 80 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 81 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 82 |
Preference Shares |
Member |
|
|
ifrs-full:PreferenceSharesMember |
| 83 |
Ordinary Shares |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 84 |
Share Options Reserve |
Member |
|
|
asln:ShareOptionsReserveMember |
| 85 |
Statement Of Changes In Equity [Line Items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 86 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 87 |
Beginning balance, share |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 88 |
Issuance of preference shares |
Concept (Shares) |
For Period |
|
asln:PreferredSharesIssued |
| 89 |
Conversion to ordinary shares from preference shares |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments |
| 90 |
Conversion to ordinary shares from preference shares, share |
Concept (Shares) |
For Period |
|
asln:ConversionOfConvertibleInstrument |
| 91 |
Adjustment of par value to NT$10 (US$0.6383) |
Concept (Monetary) |
For Period |
Credit |
asln:OrdinaryShareParValueAdjustment |
| 92 |
Issuance of new share capital (Notes 14 and 19) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 93 |
Issue of new share capital, share |
Concept (Shares) |
For Period |
|
ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued |
| 94 |
Transaction costs attributable to the issuance of ordinary shares |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShareIssueRelatedCost |
| 95 |
Issuance of ordinary shares under employee share option plan (Note 19) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughExerciseOfOptions |
| 96 |
Issuance of ordinary shares under employee share option plan, share |
Concept (Shares) |
For Period |
|
asln:IncreaseDecreaseThroughExerciseOfStockOptions |
| 97 |
Recognition of employee share options by the Company (Note 19) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions |
| 98 |
Net loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 99 |
Total comprehensive loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 100 |
Ending balance, share |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 101 |
100040 - Statement - Consolidated Statement of Changes in Equity (Parenthetical) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/StatementConsolidatedStatementOfChangesInEquityParenthetical |
| 102 |
Implied Table |
Table |
* |
* |
implied:Table |
| 103 |
Statement Of Changes In Equity [Abstract] |
Abstract |
|
|
ifrs-full:StatementOfChangesInEquityAbstract |
| 104 |
Adjustment to ordinary shares par value per share |
Concept (Share) |
As Of |
|
asln:AdjustmentToOrdinarySharesParValuePerShare |
| 105 |
100050 - Statement - Consolidated Statement of Cash Flows |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/StatementConsolidatedStatementOfCashFlows |
| 106 |
Implied Table |
Table |
* |
* |
implied:Table |
| 107 |
Statement Of Cash Flows [Abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 108 |
CASH FLOWS FROM OPERATING ACTIVITIES |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract |
| 109 |
Loss before income tax |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 110 |
Adjustments for: |
Abstract |
|
|
ifrs-full:AdjustmentsForReconcileProfitLossAbstract |
| 111 |
Depreciation expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDepreciationExpense |
| 112 |
Amortization expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForAmortisationExpense |
| 113 |
Finance costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForFinanceCosts |
| 114 |
Interest income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AdjustmentsForInterestIncome |
| 115 |
Compensation costs of share-based payment transactions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForSharebasedPayments |
| 116 |
Loss on disposal of property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment |
| 117 |
Unrealized (gain) loss on foreign exchange, net |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains |
| 118 |
Gain on disposal of licensed rights |
Concept (Monetary) |
For Period |
Debit |
asln:AdjustmentsForGainLossOnDisposalOfLicensedRight |
| 119 |
Changes in operating assets and liabilities |
Abstract |
|
|
asln:ChangesInOperatingAssetsAndLiabilitiesAbstract |
| 120 |
Increase in financial assets mandatorily classified as at fair value through profit or loss |
Concept (Monetary) |
For Period |
Credit |
asln:AdjustmentsForIncreaseInFinancialAssetsMandatorilyClassifiedAsAtFairValueThroughProfitOrLoss |
| 121 |
(Increase) decrease in accounts receivable |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable |
| 122 |
(Increase) decrease in prepayments |
Concept (Monetary) |
For Period |
Debit |
asln:AdjustmentsForIncreaseDecreaseInPrepayments |
| 123 |
Increase in trade payables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable |
| 124 |
Increase (decrease) in other payables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables |
| 125 |
Cash used in operations |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperations |
| 126 |
Interest received |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestReceivedClassifiedAsOperatingActivities |
| 127 |
Interest paid |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestPaidClassifiedAsOperatingActivities |
| 128 |
Income tax paid |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities |
| 129 |
Net cash used in operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperatingActivities |
| 130 |
CASH FLOWS FROM INVESTING ACTIVITIES |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract |
| 131 |
Payments for property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 132 |
Proceeds from disposal of property, plant and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 133 |
Payments for intangible assets |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities |
| 134 |
Increase in refundable deposits |
Concept (Monetary) |
For Period |
Debit |
asln:IncreaseDecreaseInRefundableDeposits |
| 135 |
Net cash used in investing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 136 |
CASH FLOWS FROM FINANCING ACTIVITIES |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract |
| 137 |
Proceeds from long-term borrowings |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities |
| 138 |
Repayments of long-term borrowings |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RepaymentsOfNoncurrentBorrowings |
| 139 |
Issuance of preference shares |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssueOfPreferenceShares |
| 140 |
Proceeds from new share capital |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 141 |
Proceeds from exercise of employee share options |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromExerciseOfOptions |
| 142 |
Payments for transaction costs attributable to the issuance of ordinary shares |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PaymentsForShareIssueCosts |
| 143 |
Net cash generated from financing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInFinancingActivities |
| 144 |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents |
| 145 |
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 146 |
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 147 |
100060 - Disclosure - General Information |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureGeneralInformation |
| 148 |
Implied Table |
Table |
* |
* |
implied:Table |
| 149 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group [Abstract] |
Abstract |
|
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupAbstract |
| 150 |
General Information |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory |
| 151 |
100070 - Disclosure - Approval of Financial Statements |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureApprovalOfFinancialStatements |
| 152 |
Implied Table |
Table |
* |
* |
implied:Table |
| 153 |
Disclosure Of Authorization To Issue Financial Statements [Abstract] |
Abstract |
|
|
asln:DisclosureOfAuthorizationToIssueFinancialStatementsAbstract |
| 154 |
Approval of Financial Statements |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory |
| 155 |
100080 - Disclosure - Application of New Amended and Revised Standards and Interpretations |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureApplicationOfNewAmendedAndRevisedStandardsAndInterpretations |
| 156 |
Implied Table |
Table |
* |
* |
implied:Table |
| 157 |
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract |
| 158 |
Application of New Amended and Revised Standards and Interpretations |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory |
| 159 |
100090 - Disclosure - Summary of Significant Accounting Policies |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies |
| 160 |
Implied Table |
Table |
* |
* |
implied:Table |
| 161 |
Disclosure Of Significant Accounting Policies [Abstract] |
Abstract |
|
|
asln:DisclosureOfSignificantAccountingPoliciesAbstract |
| 162 |
Summary of Significant Accounting Policies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory |
| 163 |
100100 - Disclosure - Critical Accounting Judgments and Key Sources of Estimation Uncertainty |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertainty |
| 164 |
Implied Table |
Table |
* |
* |
implied:Table |
| 165 |
Disclosure Of Accounting Judgements And Estimates [Abstract] |
Abstract |
|
|
asln:DisclosureOfAccountingJudgementsAndEstimatesAbstract |
| 166 |
Critical Accounting Judgments and Key Sources of Estimation Uncertainty |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory |
| 167 |
100110 - Disclosure - Cash and Cash Equivalents |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureCashAndCashEquivalents |
| 168 |
Implied Table |
Table |
* |
* |
implied:Table |
| 169 |
Cash And Cash Equivalents [Abstract] |
Abstract |
|
|
ifrs-full:CashAndCashEquivalentsAbstract |
| 170 |
Cash and Cash Equivalents |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory |
| 171 |
100120 - Disclosure - Financial Assets at Fair Value Through Profit or Loss |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLoss |
| 172 |
Implied Table |
Table |
* |
* |
implied:Table |
| 173 |
Financial Assets At Fair Value Through Profit Or Loss [Abstract] |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossAbstract |
| 174 |
Financial Assets at Fair Value Through Profit or Loss |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfFinancialAssetsAtFairValueThroughProfitOrLossExplanatory |
| 175 |
100130 - Disclosure - Financial Assets at Fair Value Through Other Comprehensive Income |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncome |
| 176 |
Implied Table |
Table |
* |
* |
implied:Table |
| 177 |
Financial Assets At Fair Value Through Other Comprehensive Income [Abstract] |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract |
| 178 |
Financial Assets At Fair Value Through Other Comprehensive Income |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFairValueMeasurementExplanatory |
| 179 |
100140 - Disclosure - Property, Plant And Equipment |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosurePropertyPlantAndEquipment |
| 180 |
Implied Table |
Table |
* |
* |
implied:Table |
| 181 |
Disclosure Of Property Plant And Equipment [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract |
| 182 |
Property, Plant and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory |
| 183 |
100150 - Disclosure - Intangible Assets |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIntangibleAssets |
| 184 |
Implied Table |
Table |
* |
* |
implied:Table |
| 185 |
Disclosure Of Intangible Assets [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 186 |
Intangible Assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIntangibleAssetsExplanatory |
| 187 |
100160 - Disclosure - Other Payables |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOtherPayables |
| 188 |
Implied Table |
Table |
* |
* |
implied:Table |
| 189 |
Trade And Other Payables [Abstract] |
Abstract |
|
|
ifrs-full:TradeAndOtherPayablesAbstract |
| 190 |
Other Payables |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfOtherPayablesExplanatory |
| 191 |
100170 - Disclosure - Long Term Borrowings |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLongTermBorrowings |
| 192 |
Implied Table |
Table |
* |
* |
implied:Table |
| 193 |
Borrowings [Abstract] |
Abstract |
|
|
ifrs-full:BorrowingsAbstract |
| 194 |
Long Term Borrowings |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfBorrowingsExplanatory |
| 195 |
100180 - Disclosure - Retirement Benefit Plans |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureRetirementBenefitPlans |
| 196 |
Implied Table |
Table |
* |
* |
implied:Table |
| 197 |
Disclosure Of Defined Benefit Plans [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfDefinedBenefitPlansAbstract |
| 198 |
Retirement Benefit Plans |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEmployeeBenefitsExplanatory |
| 199 |
100190 - Disclosure - Equity |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureEquity |
| 200 |
Implied Table |
Table |
* |
* |
implied:Table |
| 201 |
Equity [Abstract] |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 202 |
Equity |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfEquityExplanatory |
| 203 |
100200 - Disclosure - License Agreements |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLicenseAgreements |
| 204 |
Implied Table |
Table |
* |
* |
implied:Table |
| 205 |
Disclosure Of Transactions Between Related Parties [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract |
| 206 |
License Agreements |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfLicenseAgreementsExplanatory |
| 207 |
100210 - Disclosure - Loss Before Income Tax |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTax |
| 208 |
Implied Table |
Table |
* |
* |
implied:Table |
| 209 |
Profit Loss [Abstract] |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 210 |
Loss Before Income Tax |
Concept (Text Block (HTML)) |
For Period |
|
asln:LossBeforeIncomeTaxExplanatory |
| 211 |
100220 - Disclosure - Income Taxes |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIncomeTaxes |
| 212 |
Implied Table |
Table |
* |
* |
implied:Table |
| 213 |
Income Tax [Abstract] |
Abstract |
|
|
asln:IncomeTaxAbstract |
| 214 |
Income Taxes |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIncomeTaxExplanatory |
| 215 |
100230 - Disclosure - Loss Per Share |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossPerShare |
| 216 |
Implied Table |
Table |
* |
* |
implied:Table |
| 217 |
Earnings Per Share [Abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 218 |
Loss Per Share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEarningsPerShareExplanatory |
| 219 |
100240 - Disclosure - Share-Based Payment Arrangements |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangements |
| 220 |
Implied Table |
Table |
* |
* |
implied:Table |
| 221 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract |
| 222 |
Share-Based Payment Arrangements |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory |
| 223 |
100250 - Disclosure - Operating Lease Arrangement |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOperatingLeaseArrangement |
| 224 |
Implied Table |
Table |
* |
* |
implied:Table |
| 225 |
Disclosure Of Finance Lease And Operating Lease By Lessee [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract |
| 226 |
Operating Lease Arrangement |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory |
| 227 |
100260 - Disclosure - Capital Management |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureCapitalManagement |
| 228 |
Implied Table |
Table |
* |
* |
implied:Table |
| 229 |
Disclosure Of Capital Management [Abstract] |
Abstract |
|
|
asln:DisclosureOfCapitalManagementAbstract |
| 230 |
Capital Management |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfCapitalManagementExplanatory |
| 231 |
100270 - Disclosure - Financial Instruments |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstruments |
| 232 |
Implied Table |
Table |
* |
* |
implied:Table |
| 233 |
Disclosure Of Financial Instruments [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 234 |
Financial Instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialInstrumentsExplanatory |
| 235 |
100280 - Disclosure - Transactions with Related Parties |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureTransactionsWithRelatedParties |
| 236 |
Implied Table |
Table |
* |
* |
implied:Table |
| 237 |
Disclosure Of Transactions Between Related Parties [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract |
| 238 |
Transactions with Related Parties |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRelatedPartyExplanatory |
| 239 |
100290 - Disclosure - Segment Information |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSegmentInformation |
| 240 |
Implied Table |
Table |
* |
* |
implied:Table |
| 241 |
Disclosure Of Operating Segments [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfOperatingSegmentsAbstract |
| 242 |
Segment Information |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOperatingSegmentsExplanatory |
| 243 |
100300 - Disclosure - Summary of Significant Accounting Policies (Policies) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies |
| 244 |
Implied Table |
Table |
* |
* |
implied:Table |
| 245 |
Disclosure Of Significant Accounting Policies [Abstract] |
Abstract |
|
|
asln:DisclosureOfSignificantAccountingPoliciesAbstract |
| 246 |
Statement of compliance |
Concept (Text Block (HTML)) |
For Period |
|
asln:DescriptionOfAccountingPolicyForStatementOfComplianceExplanatory |
| 247 |
Basis of preparation |
Concept (Text Block (HTML)) |
For Period |
|
asln:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory |
| 248 |
Classification of current and non-current assets and liabilities |
Concept (Text Block (HTML)) |
For Period |
|
asln:DescriptionOfAccountingPolicyForClassificationOfCurrentAndNonCurrentAssetsAndLiabilitiesExplanatory |
| 249 |
Basis of consolidation |
Concept (Text Block (HTML)) |
For Period |
|
asln:DescriptionOfAccountingPolicyForBasisOfConsolidation |
| 250 |
Foreign currencies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory |
| 251 |
Property, plant and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory |
| 252 |
Intangible assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory |
| 253 |
Impairment of tangible and intangible assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory |
| 254 |
Financial instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory |
| 255 |
Revenue recognition |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue |
| 256 |
Research and development expenses |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory |
| 257 |
Leasing |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory |
| 258 |
Retirement benefits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory |
| 259 |
Share-based payment arrangements |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory |
| 260 |
Taxation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory |
| 261 |
100310 - Disclosure - General Information (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureGeneralInformationTables |
| 262 |
Implied Table |
Table |
* |
* |
implied:Table |
| 263 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group [Abstract] |
Abstract |
|
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupAbstract |
| 264 |
Summary of Detailed Information about Businesses and Intragroup Relationships of Group |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupExplanatory |
| 265 |
100320 - Disclosure - Application of New Amended and Revised Standards and Interpretations (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureApplicationOfNewAmendedAndRevisedStandardsAndInterpretationsTables |
| 266 |
Implied Table |
Table |
* |
* |
implied:Table |
| 267 |
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract |
| 268 |
Schedule of New, Amended or Revised Standards and Interpretations |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfNewAmendedOrRevisedStandardsAndInterpretationsExplanatory |
| 269 |
Schedule of Anticipated Impact On Assets and Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations |
| 270 |
100330 - Disclosure - Cash and cash equivalents (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureCashAndCashEquivalentsTables |
| 271 |
Implied Table |
Table |
* |
* |
implied:Table |
| 272 |
Cash And Cash Equivalents [Abstract] |
Abstract |
|
|
ifrs-full:CashAndCashEquivalentsAbstract |
| 273 |
Summary of Cash and Cash Equivalents |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationOfCashAndCashEquivalentsExplanatory |
| 274 |
100340 - Disclosure - Financial Assets at Fair Value Through Profit or Loss (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLossTables |
| 275 |
Implied Table |
Table |
* |
* |
implied:Table |
| 276 |
Financial Assets At Fair Value Through Profit Or Loss [Abstract] |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossAbstract |
| 277 |
Summary of Financial Assets at Fair Value Through Profit or Loss |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationOfFinancialAssetsAtFairValueThroughProfitOrLossExplanatory |
| 278 |
100350 - Disclosure - Financial Assets at Fair Value Through Other Comprehensive Income (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeTables |
| 279 |
Implied Table |
Table |
* |
* |
implied:Table |
| 280 |
Financial Assets At Fair Value Through Other Comprehensive Income [Abstract] |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract |
| 281 |
Summary of Financial Assets at Fair Value Through Other Comprehensive Income |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory |
| 282 |
100360 - Disclosure - Property, Plant And Equipment (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables |
| 283 |
Implied Table |
Table |
* |
* |
implied:Table |
| 284 |
Disclosure Of Property Plant And Equipment [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract |
| 285 |
Summary of Carrying Amount of Each Class of Property Plant and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory |
| 286 |
Summary of Cost and Accumulated Depreciation of Property Plant and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfCostAndAccumulatedDepreciationOfPropertyPlantAndEquipmentExplanatory |
| 287 |
Summary of Estimated Useful lives of Property Plant and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosurePropertyPlantAndEquipmentUsefulLivesForDepreciationExplanatory |
| 288 |
100370 - Disclosure - Intangible Assets (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIntangibleAssetsTables |
| 289 |
Implied Table |
Table |
* |
* |
implied:Table |
| 290 |
Disclosure Of Intangible Assets [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfIntangibleAssetsAbstract |
| 291 |
Summary of Carrying Amounts of Each Class of Intangible Assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory |
| 292 |
100380 - Disclosure - Other Payables (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOtherPayablesTables |
| 293 |
Implied Table |
Table |
* |
* |
implied:Table |
| 294 |
Trade And Other Payables [Abstract] |
Abstract |
|
|
ifrs-full:TradeAndOtherPayablesAbstract |
| 295 |
Schedule of Other Payables |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationAboutOtherPayablesExplanatory |
| 296 |
100390 - Disclosure - Long Term Borrowings (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLongTermBorrowingsTables |
| 297 |
Implied Table |
Table |
* |
* |
implied:Table |
| 298 |
Borrowings [Abstract] |
Abstract |
|
|
ifrs-full:BorrowingsAbstract |
| 299 |
Summary of Loans |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory |
| 300 |
100400 - Disclosure - Equity (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureEquityTables |
| 301 |
Implied Table |
Table |
* |
* |
implied:Table |
| 302 |
Equity [Abstract] |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 303 |
Schedule of Ordinary Shares |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfOrdinarySharesExplanatory |
| 304 |
Schedule of Capital Surplus |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfCapitalSurplusExplanatory |
| 305 |
Schedule of Accumulated Deficits |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfAccumulatedDeficitsExplanatory |
| 306 |
100410 - Disclosure - Loss Before Income Tax (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTaxTables |
| 307 |
Implied Table |
Table |
* |
* |
implied:Table |
| 308 |
Profit Loss [Abstract] |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 309 |
Schedule of Other Gains and Losses |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationOtherGainsAndLossesExplanatory |
| 310 |
Summary of Finance costs |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceCostExplanatory |
| 311 |
Schedule of Depreciation and Amortization |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory |
| 312 |
Schedule of Employee Benefits Expense |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfEmployeeBenefitsExpenseExplanatory |
| 313 |
100420 - Disclosure - Income Taxes (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIncomeTaxesTables |
| 314 |
Implied Table |
Table |
* |
* |
implied:Table |
| 315 |
Income Tax [Abstract] |
Abstract |
|
|
asln:IncomeTaxAbstract |
| 316 |
Summary of Income Tax Recognized in Profit or Loss |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfIncomeTaxRecognizedInProfitOrLossExplanatory |
| 317 |
Summary of Reconciliation of Accounting Profit and Income Tax Expense |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory |
| 318 |
100430 - Disclosure - Loss Per Share (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossPerShareTables |
| 319 |
Implied Table |
Table |
* |
* |
implied:Table |
| 320 |
Earnings Per Share [Abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 321 |
Summary of Earnings Per Share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:EarningsPerShareExplanatory |
| 322 |
Summary of Loss and Weighted-Average Number of Ordinary Shares Outstanding |
Concept (Text Block (HTML)) |
For Period |
|
asln:LossAndWeightedAverageNumberOfOrdinarySharesOutstandingExplanatory |
| 323 |
100440 - Disclosure - Share-Based Payment Arrangements (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsTables |
| 324 |
Implied Table |
Table |
* |
* |
implied:Table |
| 325 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract |
| 326 |
Summary of Fair Value of Share Options Granted to Employees |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationAboutFairValueOfShareOptionsGrantedToEmployeesExplanatory |
| 327 |
Summary of Employee Share Options |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory |
| 328 |
Summary of Outstanding Options |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory |
| 329 |
Summary of Options Granted Priced Using Binomial Option Pricing Model |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfOptionsGrantedPricedUsingBinomialOptionPricingModelExplanatory |
| 330 |
Summary of Long Term Incentive Plan |
Concept (Text Block (HTML)) |
For Period |
|
asln:DisclosureOfDetailedInformationOfLongTermIncentivePlanExplanatory |
| 331 |
100450 - Disclosure - Operating Lease Arrangement (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOperatingLeaseArrangementTables |
| 332 |
Implied Table |
Table |
* |
* |
implied:Table |
| 333 |
Disclosure Of Finance Lease And Operating Lease By Lessee [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract |
| 334 |
Schedule of Future Minimum Lease Payments of Non - Cancellable Operating Lease Commitments |
Concept (Text Block (HTML)) |
For Period |
|
asln:ScheduleOfFutureMinimumLeasePaymentsOfNonCancellableOperatingLeaseCommitmentsExplanatory |
| 335 |
100460 - Disclosure - Financial Instruments (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstrumentsTables |
| 336 |
Implied Table |
Table |
* |
* |
implied:Table |
| 337 |
Disclosure Of Financial Instruments [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 338 |
Fair Value of Financial Instruments Measured at Fair Value on Recurring Basis |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialAssetsExplanatory |
| 339 |
Summary of Categories of Financial Instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory |
| 340 |
Summary of Group's Significant Financial Assets and Liabilities Denominated in Foreign Currencies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory |
| 341 |
Sensitivity Analysis of Foreign Currency Risk |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk |
| 342 |
100470 - Disclosure - Transactions with Related Parties (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureTransactionsWithRelatedPartiesTables |
| 343 |
Implied Table |
Table |
* |
* |
implied:Table |
| 344 |
Disclosure Of Transactions Between Related Parties [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract |
| 345 |
Schedule of Key Management Personnel Compensation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory |
| 346 |
100480 - Disclosure - Segment Information (Tables) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSegmentInformationTables |
| 347 |
Implied Table |
Table |
* |
* |
implied:Table |
| 348 |
Disclosure Of Operating Segments [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfOperatingSegmentsAbstract |
| 349 |
Analysis of the Group Revenue from Major Products and Services |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory |
| 350 |
100490 - Disclosure - General Information - Summary of Detailed Information about Businesses and Intragroup Relationships of Group (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureGeneralInformationSummaryOfDetailedInformationAboutBusinessesAndIntragroupRelationshipsOfGroupDetails |
| 351 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group [Table] |
Table |
* |
* |
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupTable |
| 352 |
Subsidiaries [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInSubsidiariesAxis |
| 353 |
Entity's total for subsidiaries [member] |
Member |
|
|
ifrs-full:EntitysTotalForSubsidiariesMember |
| 354 |
ASLAN Pharmaceuticals Limited Cayman Islands |
Member |
|
|
asln:ASLANPharmaceuticalsLimitedCaymanIslandsMember |
| 355 |
ASLAN Pharmaceuticals Pte Ltd Singapore |
Member |
|
|
asln:ASLANPharmaceuticalsPteLtdSingaporeMember |
| 356 |
ASLAN Pharmaceuticals Taiwan Limited |
Member |
|
|
asln:ASLANPharmaceuticalsTaiwanLimitedMember |
| 357 |
ASLAN Pharmaceuticals Australia Pty Ltd |
Member |
|
|
asln:ASLANPharmaceuticalsAustraliaPtyLtdMember |
| 358 |
ASLAN Pharmaceuticals Hong Kong Limited |
Member |
|
|
asln:ASLANPharmaceuticalsHongKongLimitedMember |
| 359 |
ASLAN Pharmaceuticals Shanghai Co Ltd |
Member |
|
|
asln:ASLANPharmaceuticalsShanghaiCoLtdMember |
| 360 |
ASLAN Pharmaceuticals USA Inc |
Member |
|
|
asln:ASLANPharmaceuticalsUSAIncMember |
| 361 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group [Abstract] |
Abstract |
|
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupAbstract |
| 362 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group Line Item |
Abstract |
|
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupLineItem |
| 363 |
Name Of Reporting Entity Or Other Means Of Identification |
Concept (Text/String) |
For Period |
|
ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification |
| 364 |
Country Of Incorporation |
Concept (Text/String) |
For Period |
|
ifrs-full:CountryOfIncorporation |
| 365 |
Date Of Incorporation |
Concept (Year/Month) |
For Period |
|
asln:DateOfIncorporation |
| 366 |
Main Business Of Group |
Concept (Text/String) |
For Period |
|
asln:MainBusinessOfGroup |
| 367 |
100490 - Disclosure - General Information - Summary of Detailed Information about Businesses and Intragroup Relationships of Group (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureGeneralInformationSummaryOfDetailedInformationAboutBusinessesAndIntragroupRelationshipsOfGroupDetails |
| 368 |
Implied Table |
Table |
* |
* |
implied:Table |
| 369 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group [Abstract] |
Abstract |
|
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupAbstract |
| 370 |
Disclosure Of Detailed Information About Businesses And Intragroup Relationship Of Group Line Item |
Abstract |
|
|
asln:DisclosureOfDetailedInformationAboutBusinessesAndIntragroupRelationshipOfGroupLineItem |
| 371 |
Name |
Concept (Text/String) |
For Period |
|
ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification |
| 372 |
Place of Incorporation |
Concept (Text/String) |
For Period |
|
ifrs-full:CountryOfIncorporation |
| 373 |
Date of Incorporation |
Concept (Year/Month) |
For Period |
|
asln:DateOfIncorporation |
| 374 |
Main Business |
Concept (Text/String) |
For Period |
|
asln:MainBusinessOfGroup |
| 375 |
100500 - Disclosure - Application of New Amended and Revised Standards and Interpretations - Schedule of New Amended or Revised Standards and Interpretations (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureApplicationOfNewAmendedAndRevisedStandardsAndInterpretationsScheduleOfNewAmendedOrRevisedStandardsAndInterpretationsDetails |
| 376 |
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Table] |
Table |
* |
* |
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable |
| 377 |
New IFRSs [axis] |
Axis |
|
|
ifrs-full:NewIFRSsAxis |
| 378 |
New IFRSs [member] |
Member |
|
|
ifrs-full:NewIFRSsMember |
| 379 |
Annual Improvements to IFRSs 2015-2017 Cycle |
Member |
|
|
asln:AnnualImprovementsToIFRSs2015To2017CycleMember |
| 380 |
Amendments To IFRS9 |
Member |
|
|
asln:AmendmentsToIFRS9Member |
| 381 |
IFRS 16 |
Member |
|
|
asln:IFRS16Member |
| 382 |
Amendments To IAS 19 |
Member |
|
|
asln:AmendmentsToIAS19Member |
| 383 |
Amendments To IAS 28 |
Member |
|
|
asln:AmendmentsToIAS28Member |
| 384 |
IFRIC 23 |
Member |
|
|
asln:IFRIC23Member |
| 385 |
Amendments To IFRS 3 |
Member |
|
|
asln:AmendmentsToIFRS3Member |
| 386 |
Amendments To IFRS 10 And IAS 28 |
Member |
|
|
asln:AmendmentsToIFRS10AndIAS28Member |
| 387 |
IFRS 17 |
Member |
|
|
asln:IFRS17Member |
| 388 |
Amendments To IAS 1 And IAS 8 |
Member |
|
|
asln:AmendmentsToIAS1AndIAS8Member |
| 389 |
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items] |
LineItems |
|
|
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems |
| 390 |
New, Amended or Revised Standards and Interpretations |
Concept (Text/String) |
For Period |
|
ifrs-full:TitleOfNewIFRS |
| 391 |
Effective Date Announced by IASB |
Concept (Date) |
For Period |
|
ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially |
| 392 |
100510 - Disclosure - Application of New Amended and Revised Standards and Interpretations - Schedule of Anticipated Impact On Assets and Liabilities (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureApplicationOfNewAmendedAndRevisedStandardsAndInterpretationsScheduleOfAnticipatedImpactOnAssetsAndLiabilitiesDetails |
| 393 |
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Table] |
Table |
* |
* |
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable |
| 394 |
Initially applied IFRSs [axis] |
Axis |
|
|
ifrs-full:InitiallyAppliedIFRSsAxis |
| 395 |
Initially applied IFRSs [member] |
Member |
|
|
ifrs-full:InitiallyAppliedIFRSsMember |
| 396 |
Adjustments Arising from Initial Application |
Member |
|
|
asln:AdjustmentsArisingFromInitialApplicationMember |
| 397 |
Non-adjusting events after reporting period [axis] |
Axis |
|
|
ifrs-full:NonadjustingEventsAfterReportingPeriodAxis |
| 398 |
Non-adjusting events after reporting period [member] |
Member |
|
|
ifrs-full:NonadjustingEventsMember |
| 399 |
Adjusted |
Member |
|
|
asln:AdjustedMember |
| 400 |
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items] |
LineItems |
|
|
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems |
| 401 |
Total effect on assets (right-of-use assets) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:RightofuseAssets |
| 402 |
Lease liabilities - current |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLeaseLiabilities |
| 403 |
Lease liabilities - non-current |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLeaseLiabilities |
| 404 |
Total effect on liabilities |
Concept (Monetary) |
As Of |
|
asln:EffectOnLiabilities |
| 405 |
100520 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails |
| 406 |
Implied Table |
Table |
* |
* |
implied:Table |
| 407 |
Disclosure Of Significant Accounting Policies [Abstract] |
Abstract |
|
|
asln:DisclosureOfSignificantAccountingPoliciesAbstract |
| 408 |
Impairment loss recognized for the asset or cash-generating unit |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ImpairmentLoss |
| 409 |
Remaining performance obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations |
| 410 |
100530 - Disclosure - Critical Accounting Judgments and Key Sources of Estimation Uncertainty - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureCriticalAccountingJudgmentsAndKeySourcesOfEstimationUncertaintyAdditionalInformationDetails |
| 411 |
Implied Table |
Table |
* |
* |
implied:Table |
| 412 |
Disclosure Of Accounting Judgements And Estimates [Abstract] |
Abstract |
|
|
asln:DisclosureOfAccountingJudgementsAndEstimatesAbstract |
| 413 |
Deferred tax assets recognized on tax losses |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DeferredTaxAssets |
| 414 |
100540 - Disclosure - Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalentsDetails |
| 415 |
Implied Table |
Table |
* |
* |
implied:Table |
| 416 |
Cash And Cash Equivalents [Abstract] |
Abstract |
|
|
ifrs-full:CashAndCashEquivalentsAbstract |
| 417 |
Cash on hand |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashOnHand |
| 418 |
Deposits in banks |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:BalancesWithBanks |
| 419 |
Cash |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Cash |
| 420 |
100550 - Disclosure - Financial Assets at Fair Value Through Profit or Loss - Summary of Financial Assets at Fair Value Through Profit or Loss (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughProfitOrLossSummaryOfFinancialAssetsAtFairValueThroughProfitOrLossDetails |
| 421 |
Implied Table |
Table |
* |
* |
implied:Table |
| 422 |
Financial Assets At Fair Value Through Profit Or Loss [Abstract] |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossAbstract |
| 423 |
Financial assets at fair value through profit or loss (Notes 4, 7 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss |
| 424 |
100560 - Disclosure - Financial Assets at Fair Value Through Other Comprehensive Income - Summary of Financial Assets at Fair Value Through Other Comprehensive Income (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeSummaryOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncomeDetails |
| 425 |
Implied Table |
Table |
* |
* |
implied:Table |
| 426 |
Financial Assets At Fair Value Through Other Comprehensive Income [Abstract] |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract |
| 427 |
Financial assets at fair value through other comprehensive income (Notes 4, 8 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome |
| 428 |
100570 - Disclosure - Property, Plant and Equipment - Summary of Carrying Amount of Each Class of Property Plant and Equipment (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfCarryingAmountOfEachClassOfPropertyPlantAndEquipmentDetails |
| 429 |
Disclosure Of Property Plant And Equipment [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 430 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 431 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 432 |
Office Equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 433 |
Other Equipment |
Member |
|
|
asln:OtherEquipmentMember |
| 434 |
Leasehold Improvements |
Member |
|
|
ifrs-full:LeaseholdImprovementsMember |
| 435 |
Disclosure Of Property Plant And Equipment [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 436 |
Property Plant And Equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 437 |
100580 - Disclosure - Property, Plant and Equipment - Summary of Cost and Accumulated Depreciation of Property Plant and Equipment (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfCostAndAccumulatedDepreciationOfPropertyPlantAndEquipmentDetails |
| 438 |
Disclosure Of Property Plant And Equipment [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 439 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 440 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 441 |
Office Equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 442 |
Other Equipment |
Member |
|
|
asln:OtherEquipmentMember |
| 443 |
Leasehold Improvements |
Member |
|
|
ifrs-full:LeaseholdImprovementsMember |
| 444 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 445 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 446 |
Gross carrying amount |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 447 |
Accumulated depreciation, amortisation and impairment |
Member |
|
|
ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember |
| 448 |
Disclosure Of Property Plant And Equipment [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 449 |
Beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 450 |
Additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment |
| 451 |
Depreciation expenses |
Concept (Monetary) |
For Period |
|
ifrs-full:DepreciationPropertyPlantAndEquipment |
| 452 |
Disposals |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsPropertyPlantAndEquipment |
| 453 |
Ending balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 454 |
100590 - Disclosure - Property, Plant and Equipment - Summary of Estimated Useful Lives of Property Plant and Equipment (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails |
| 455 |
Disclosure Of Property Plant And Equipment [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 456 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 457 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 458 |
Office Equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 459 |
Other Equipment |
Member |
|
|
asln:OtherEquipmentMember |
| 460 |
Leasehold Improvements |
Member |
|
|
ifrs-full:LeaseholdImprovementsMember |
| 461 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 462 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 463 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 464 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 465 |
Disclosure Of Property Plant And Equipment [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 466 |
Useful lives |
Concept (Text/String) |
For Period |
|
ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment |
| 467 |
100600 - Disclosure - Intangible Assets - Summary of Carrying Amounts of Each Class of Intangible Assets (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfCarryingAmountsOfEachClassOfIntangibleAssetsDetails |
| 468 |
Disclosure Of Intangible Assets [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 469 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 470 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 471 |
Licences |
Member |
|
|
ifrs-full:LicencesMember |
| 472 |
Computer Software |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 473 |
Disclosure Of Intangible Assets [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 474 |
Intangible assets (Notes 4, 5, 10 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 475 |
100610 - Disclosure - Intangible Assets - Summary of Cost and Accumulated Amortization of Intangible Assets (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIntangibleAssetsSummaryOfCostAndAccumulatedAmortizationOfIntangibleAssetsDetails |
| 476 |
Disclosure Of Intangible Assets [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 477 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 478 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 479 |
Licences |
Member |
|
|
ifrs-full:LicencesMember |
| 480 |
Computer Software |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 481 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 482 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 483 |
Gross carrying amount |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 484 |
Accumulated depreciation, amortisation and impairment |
Member |
|
|
ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember |
| 485 |
Disclosure Of Intangible Assets [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 486 |
Beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 487 |
Additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill |
| 488 |
Amortization expenses |
Concept (Monetary) |
For Period |
|
ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill |
| 489 |
Ending balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 490 |
100620 - Disclosure - Intangible Assets - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails |
| 491 |
Disclosure Of Intangible Assets [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 492 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 493 |
Intangible assets other than goodwill [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 494 |
Computer Software |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 495 |
Disclosure Of Intangible Assets [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 496 |
Impairment loss recognized |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 497 |
Estimated useful lives |
Concept (Text/String) |
For Period |
|
ifrs-full:UsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwill |
| 498 |
100630 - Disclosure - Other Payables - Schedule of Other Payables (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOtherPayablesScheduleOfOtherPayablesDetails |
| 499 |
Implied Table |
Table |
* |
* |
implied:Table |
| 500 |
Trade And Other Payables [Abstract] |
Abstract |
|
|
ifrs-full:TradeAndOtherPayablesAbstract |
| 501 |
Payables for salaries and bonuses |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ShorttermEmployeeBenefitsAccruals |
| 502 |
Payables for professional fees |
Concept (Monetary) |
As Of |
Credit |
asln:PayablesForProfessionalFeesCurrent |
| 503 |
Payables for cash-settled share-based payment transactions (Note 19) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentRecognisedLiabilitiesDefinedBenefitPlan |
| 504 |
Interest payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:InterestPayable |
| 505 |
Others |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherLiabilities |
| 506 |
Other Payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherCurrentPayables |
| 507 |
100640 - Disclosure - Long Term Borrowings - Summary of Loans (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLongTermBorrowingsSummaryOfLoansDetails |
| 508 |
Disclosure Of Detailed Information About Borrowings [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable |
| 509 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 510 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 511 |
Loans from Government |
Member |
|
|
asln:LoansFromGovernmentMember |
| 512 |
Other Long-term Borrowings |
Member |
|
|
asln:OtherLongTermBorrowingsMember |
| 513 |
Interest Payables |
Member |
|
|
asln:InterestPayablesMember |
| 514 |
Disclosure Of Detailed Information About Borrowings [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems |
| 515 |
Long-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LongtermBorrowings |
| 516 |
100650 - Disclosure - Long Term Borrowings - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLongTermBorrowingsAdditionalInformationDetails |
| 517 |
Disclosure Of Detailed Information About Borrowings [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable |
| 518 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 519 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 520 |
Loans from Government |
Member |
|
|
asln:LoansFromGovernmentMember |
| 521 |
Loans from Government |
Member |
|
|
asln:LoansFromGovernmentAndInterestPayablesMember |
| 522 |
CSL Finance Pty Ltd |
Member |
|
|
asln:CSLFinancePtyLtdMember |
| 523 |
Other Long-term Borrowings |
Member |
|
|
asln:OtherLongTermBorrowingsMember |
| 524 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 525 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 526 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 527 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 528 |
Disclosure Of Detailed Information About Borrowings [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems |
| 529 |
Long-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LongtermBorrowings |
| 530 |
Loan repayable period |
Concept (Text/String) |
For Period |
|
ifrs-full:BorrowingsMaturity |
| 531 |
Borrowings, interest rate |
Concept (Percent) |
As Of |
|
ifrs-full:BorrowingsInterestRate |
| 532 |
Loan facility |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:UndrawnBorrowingFacilities |
| 533 |
Percentage of based on research and development costs |
Concept (Percent) |
For Period |
|
asln:PercentageOfResearchAndDevelopmentCosts |
| 534 |
loan repayable period |
Concept (xbrli:durationItemType) |
For Period |
|
asln:LoanRepayablePeriod |
| 535 |
Borrowings Interest rate |
Concept (Text/String) |
For Period |
|
ifrs-full:BorrowingsInterestRateBasis |
| 536 |
Long-term Borrowings Including Interest |
Concept (Monetary) |
As Of |
Credit |
asln:LongtermBorrowingsIncludingInterest |
| 537 |
100660 - Disclosure - Retirement Benefits Plans - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureRetirementBenefitsPlansAdditionalInformationDetails |
| 538 |
Disclosure Of Defined Benefit Plans [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfDefinedBenefitPlansTable |
| 539 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 540 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 541 |
Defined Contribution Plans |
Member |
|
|
asln:DefinedContributionPlansMember |
| 542 |
Disclosure Of Defined Benefit Plans [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfDefinedBenefitPlansLineItems |
| 543 |
Employer contribution percentage |
Concept (Percent) |
For Period |
|
asln:EmployerContributionPercentage |
| 544 |
Employee benefits expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans |
| 545 |
100670 - Disclosure - Equity - Schedule of Ordinary Shares (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureEquityScheduleOfOrdinarySharesDetails |
| 546 |
Implied Table |
Table |
* |
* |
implied:Table |
| 547 |
Equity [Abstract] |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 548 |
Number of shares authorized |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesAuthorised |
| 549 |
Amount of shares authorized (NT$ thousand) |
Concept (Monetary) |
As Of |
Credit |
asln:AuthorizedCapital |
| 550 |
Number of shares issued and fully paid |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssuedAndFullyPaid |
| 551 |
Ordinary shares |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 552 |
100680 - Disclosure - Equity - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureEquityAdditionalInformationDetails |
| 553 |
Statement Of Changes In Equity [Table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 554 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 555 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 556 |
Ordinary Shares |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 557 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 558 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 559 |
Initial Public Offering |
Member |
|
|
asln:InitialPublicOfferingMember |
| 560 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 561 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 562 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 563 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 564 |
Statement Of Changes In Equity [Line Items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 565 |
Par value per shares |
Concept (Share) |
As Of |
|
ifrs-full:ParValuePerShare |
| 566 |
Number of preference shares approved to be converted into equal number of ordinary shares |
Concept (Shares) |
As Of |
|
asln:NumberOfPreferenceSharesApprovedToBeConvertedIntoEqualNumberOfOrdinaryShares |
| 567 |
Increase through changes in equity |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity |
| 568 |
Capital surplus |
Concept (Monetary) |
As Of |
Credit |
asln:CapitalSurplus |
| 569 |
Share split ratio |
Concept (Percent) |
For Period |
|
asln:ShareSplitRatio |
| 570 |
Number of shares issued |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 571 |
Consideration per share |
Concept (Share) |
As Of |
|
asln:ValueOfConsiderationPerShareIssued |
| 572 |
Ordinary shares |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 573 |
Amount of issuance of ordinary shares |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 574 |
Increase of share capital |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 575 |
Weighted-average bid price per share |
Concept (Share) |
For Period |
|
asln:WeightedAverageBidPricePerShare |
| 576 |
Proceeds from new share capital |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 577 |
Offering price per share |
Concept (Share) |
For Period |
|
asln:OfferingPricePerShare |
| 578 |
Amount of shares authorized |
Concept (Monetary) |
As Of |
Credit |
asln:AuthorizedCapital |
| 579 |
100690 - Disclosure - Equity - Schedule of Capital Surplus (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureEquityScheduleOfCapitalSurplusDetails |
| 580 |
Implied Table |
Table |
* |
* |
implied:Table |
| 581 |
Equity [Abstract] |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 582 |
Arising from issuance of new share capital |
Concept (Monetary) |
As Of |
Credit |
asln:ArisingFromIssuanceOfNewShareCapital |
| 583 |
Arising from employee share options |
Concept (Monetary) |
As Of |
Credit |
asln:ArisingFromEmployeeShareOptions |
| 584 |
Total |
Concept (Monetary) |
As Of |
Credit |
asln:CapitalSurplus |
| 585 |
100700 - Disclosure - Equity - Schedule of Accumulated Deficits (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureEquityScheduleOfAccumulatedDeficitsDetails |
| 586 |
Implied Table |
Table |
* |
* |
implied:Table |
| 587 |
Equity [Abstract] |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 588 |
Accumulated deficits at the beginning of the year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 589 |
Net loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 590 |
Accumulated deficits at the end of the year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 591 |
100710 - Disclosure - License Agreements - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails |
| 592 |
Disclosure Of Transactions Between Related Parties [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable |
| 593 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 594 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 595 |
Array Biopharma |
Member |
|
|
asln:ArrayBiopharmaMember |
| 596 |
Bristol-Myers Squibb |
Member |
|
|
asln:BristolMyersSquibbMember |
| 597 |
Almirall |
Member |
|
|
asln:AlmirallMember |
| 598 |
CSL Limited |
Member |
|
|
asln:CSLLimitedMember |
| 599 |
Hyundai Pharm Co., Ltd. |
Member |
|
|
asln:HyundaiPharmCoLtdMember |
| 600 |
Exploit Technologies Pte Ltd |
Member |
|
|
asln:ExploitTechnologiesPteLtdMember |
| 601 |
Nanyang Technological University |
Member |
|
|
asln:NanyangTechnologicalUniversityMember |
| 602 |
BioGenetics Co. Ltd |
Member |
|
|
asln:BioGeneticsCoLtdMember |
| 603 |
Types of contracts [axis] |
Axis |
|
|
ifrs-full:TypesOfContractsAxis |
| 604 |
Types of contracts [member] |
Member |
|
|
ifrs-full:TypesOfContractsMember |
| 605 |
License Agreements |
Member |
|
|
asln:LicenseAgreementsMember |
| 606 |
Buy Back of Rights to Commercialize |
Member |
|
|
asln:BuyBackRightsToCommercializeMember |
| 607 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 608 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 609 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 610 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 611 |
Disclosure Of Transactions Between Related Parties [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems |
| 612 |
Percentage of out-licensing proceeds agreed to pay out as royalties |
Concept (Percent) |
For Period |
|
asln:PercentageOfOutLicensingProceedsAgreedToPayOutAsRoyalties |
| 613 |
Initial upfront payment |
Concept (Monetary) |
For Period |
Debit |
asln:InitialUpfrontPayment |
| 614 |
Additional payment |
Concept (Monetary) |
For Period |
Debit |
asln:AdditionalInitialUpfrontPayment |
| 615 |
Development milestone linked payments estimated |
Concept (Monetary) |
For Period |
Debit |
asln:DevelopmentMilestoneLinkedPaymentsEstimated |
| 616 |
Regulatory milestones linked payments estimated |
Concept (Monetary) |
For Period |
Debit |
asln:RegulatoryMilestonesLinkedPaymentsEstimated |
| 617 |
Commercial milestones linked payments estimated |
Concept (Monetary) |
For Period |
Debit |
asln:CommercialMilestonesLinkedPaymentsEstimated |
| 618 |
Percentage of upfront receivable |
Concept (Percent) |
For Period |
|
asln:PercentageOfUpfrontReceivable |
| 619 |
Percentage of sublicense agreement ceiling |
Concept (Percent) |
For Period |
|
asln:PercentageOfSublicenseAgreementCeiling |
| 620 |
Notice period for termination of agreement |
Concept (xbrli:durationItemType) |
For Period |
|
asln:NoticePeriodForTerminationOfAgreement |
| 621 |
Purchase of related research materials, supplies, research documentation and clinical trial results |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PurchasesOfGoodsRelatedPartyTransactions |
| 622 |
Revenue recognized |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromRenderingOfServices |
| 623 |
Agreement date |
Concept (Date) |
For Period |
|
asln:DateOfAgreement |
| 624 |
Agreement amended date |
Concept (Date) |
For Period |
|
asln:DateOfAgreementAmended |
| 625 |
Percentage of entity's revenue |
Concept (Percent) |
For Period |
|
asln:PercentageOfLicensingRevenue |
| 626 |
Option payment received |
Concept (Monetary) |
For Period |
Debit |
asln:CollaborativeArrangementOptionPaymentReceived |
| 627 |
Payment to third parties as payment for proceeds from out-licensing agreement |
Concept (Monetary) |
For Period |
Debit |
asln:PaymentToThirdPartiesAsPaymentForProceedsFromOutLicensingAgreement |
| 628 |
Payment to buy back the rights to commercialize |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PaymentsFromContractsHeldForDealingOrTradingPurpose |
| 629 |
Additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill |
| 630 |
Milestone payment receivable upon achievement |
Concept (Monetary) |
For Period |
Debit |
asln:MilestonePaymentToBeReceivedUponMilestoneAchievement |
| 631 |
Collaboration agreement, term (in years) |
Concept (xbrli:durationItemType) |
For Period |
|
asln:CollaborationAgreementTerm |
| 632 |
Number of targets to select |
Concept (Integer) |
For Period |
|
asln:NumberOfTargetsToSelect |
| 633 |
Number of shares received in exchange for surrender of residual rights |
Concept (Shares) |
For Period |
|
asln:NumberOfSharesReceivedInExchangeForSurrenderOfResidualRights |
| 634 |
Value of shares received in exchange for surrender of residual rights |
Concept (Monetary) |
For Period |
Credit |
asln:ValueOfSharesReceivedInExchangeForSurrenderOfResidualRights |
| 635 |
Subscription price |
Concept (Share) |
For Period |
|
asln:SubscriptionPrice |
| 636 |
Gain from derecognition recorded as other income |
Concept (Monetary) |
For Period |
Credit |
asln:GainLossArisingFromDerecognitionRecordedAsOtherIncome |
| 637 |
Upfront payment |
Concept (Monetary) |
As Of |
Credit |
asln:PaymentForLicenseUpfrontFees |
| 638 |
Sales and development milestone payments |
Concept (Monetary) |
For Period |
Credit |
asln:SalesAndDevelopmentMilestonePayments |
| 639 |
Remaining performance obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations |
| 640 |
100720 - Disclosure - Loss Before Income Tax - Schedule of Other Gains and Losses (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTaxScheduleOfOtherGainsAndLossesDetails |
| 641 |
Implied Table |
Table |
* |
* |
implied:Table |
| 642 |
Profit Loss [Abstract] |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 643 |
Net foreign exchange gains (losses) |
Concept (Monetary) |
For Period |
Credit |
asln:NetForeignExchangeGainLoss |
| 644 |
Fair value changes of financial assets mandatorily classified as at FVTPL |
Concept (Monetary) |
For Period |
Credit |
asln:AdjustmentsForIncreaseInFinancialAssetsMandatorilyClassifiedAsAtFairValueThroughProfitOrLoss |
| 645 |
Loss on disposal of property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment |
| 646 |
Others |
Concept (Monetary) |
For Period |
Credit |
asln:MiscellaneousOtherGainsLosses |
| 647 |
Other gains and losses |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherGainsLosses |
| 648 |
100730 - Disclosure - Loss Before Income Tax - Summary of Finance costs (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTaxSummaryOfFinanceCostsDetails |
| 649 |
Implied Table |
Table |
* |
* |
implied:Table |
| 650 |
Profit Loss [Abstract] |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 651 |
Interest on government loans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestExpense |
| 652 |
Preference share dividends |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentToProfitLossForPreferenceShareDividends |
| 653 |
Interest on CSL loan |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestExpenseOnBankLoansAndOverdrafts |
| 654 |
Other interest expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherFinanceCost |
| 655 |
Finance costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 656 |
100740 - Disclosure - Loss Before Income Tax - Schedule of Depreciation and Amortization (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTaxScheduleOfDepreciationAndAmortizationDetails |
| 657 |
Disclosure Of Property Plant And Equipment [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 658 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 659 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 660 |
Property, Plant and Equipment |
Member |
|
|
ifrs-full:OtherPropertyPlantAndEquipmentMember |
| 661 |
Computer Software |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 662 |
Disclosure Of Property Plant And Equipment [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 663 |
Depreciation and amortization |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DepreciationAndAmortisationExpense |
| 664 |
100750 - Disclosure - Loss Before Income Tax - Schedule of Employee Benefits Expense (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTaxScheduleOfEmployeeBenefitsExpenseDetails |
| 665 |
Implied Table |
Table |
* |
* |
implied:Table |
| 666 |
Profit Loss [Abstract] |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 667 |
Short-term benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ShorttermEmployeeBenefitsExpense |
| 668 |
Post-employment benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans |
| 669 |
Share-based payments (Note 19) |
Abstract |
|
|
ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract |
| 670 |
Equity-settled |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets |
| 671 |
Cash-settled |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets |
| 672 |
Total employee benefits expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 673 |
An analysis of employee benefits expense by function |
Abstract |
|
|
ifrs-full:ClassesOfEmployeeBenefitsExpenseAbstract |
| 674 |
General and administrative expenses |
Concept (Monetary) |
For Period |
Debit |
asln:EmployeeBenefitsExpenseRelatedToGeneralAndAdministrativeFunction |
| 675 |
Research and development expenses |
Concept (Monetary) |
For Period |
Debit |
asln:EmployeeBenefitsExpenseRelatedToResearchAndDevelopment |
| 676 |
Total employee benefits expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 677 |
100770 - Disclosure - Loss Before Income Tax - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossBeforeIncomeTaxAdditionalInformationDetails |
| 678 |
Disclosure Of Employee Compensation And Remuneration Of Directors [Table] |
Table |
* |
* |
asln:DisclosureOfEmployeeCompensationAndRemunerationOfDirectorsTable |
| 679 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 680 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 681 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 682 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 683 |
Disclosure Of Employee Compensation And Remuneration Of Directors [Line Items] |
LineItems |
|
|
asln:DisclosureOfEmployeeCompensationAndRemunerationOfDirectorsLineItems |
| 684 |
Percentage of accrued employees’ compensation and remuneration of directors |
Concept (Percent) |
For Period |
|
asln:AccruedEmployeesCompensationAndRemunerationPercentage |
| 685 |
Amount of accrued employees’ compensation and remuneration of directors |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DirectorsRemunerationExpense |
| 686 |
100780 - Disclosure - Income Taxes - Summary of Income Tax Recognized in Profit or Loss (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxRecognizedInProfitOrLossDetails |
| 687 |
Implied Table |
Table |
* |
* |
implied:Table |
| 688 |
Major Components Of Tax Expense Income [Abstract] |
Abstract |
|
|
ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract |
| 689 |
Current tax |
Abstract |
|
|
ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract |
| 690 |
Adjustments for prior periods |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod |
| 691 |
100790 - Disclosure - Income Taxes - Summary of Reconciliation of Accounting Profit and Income Tax Expense (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfAccountingProfitAndIncomeTaxExpenseDetails |
| 692 |
Implied Table |
Table |
* |
* |
implied:Table |
| 693 |
Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates [Abstract] |
Abstract |
|
|
ifrs-full:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract |
| 694 |
Loss before income tax |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AccountingProfit |
| 695 |
Income tax benefit calculated at the statutory rate |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxExpenseIncomeAtApplicableTaxRate |
| 696 |
Nondeductible expenses in determining taxable income |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss |
| 697 |
Tax credits for research and development expenditures |
Concept (Monetary) |
For Period |
Credit |
asln:TaxCreditsRelatedToExpenditureOnResearchAndDevelopment |
| 698 |
Unrecognized loss carryforward |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfTaxLosses |
| 699 |
Effect of different tax rates of group entities operating in other jurisdictions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome |
| 700 |
Adjustments for prior periods |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod |
| 701 |
Income tax expense recognized in profit or loss |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 702 |
100800 - Disclosure - Income Taxes - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails |
| 703 |
Major Components Of Tax Expense Income [Table] |
Table |
* |
* |
asln:MajorComponentsOfTaxExpenseIncomeTable |
| 704 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 705 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 706 |
Singapore |
Member |
|
|
country:SG |
| 707 |
Taiwan |
Member |
|
|
country:TW |
| 708 |
Australia |
Member |
|
|
country:AU |
| 709 |
Hong Kong |
Member |
|
|
country:HK |
| 710 |
China |
Member |
|
|
country:CN |
| 711 |
United States of America |
Member |
|
|
country:US |
| 712 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 713 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 714 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 715 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 716 |
Major Components Of Tax Expense Income [Line Items] |
LineItems |
|
|
asln:MajorComponentsOfTaxExpenseIncomeLineItems |
| 717 |
Statutory corporate income tax rate |
Concept (Percent) |
For Period |
|
ifrs-full:ApplicableTaxRate |
| 718 |
Unrecognized loss carryforward |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfTaxLosses |
| 719 |
Deferred tax assets recognized on tax losses |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DeferredTaxAssets |
| 720 |
Decrease in unappropriated earnings due to the effect of corporate surtax rate |
Concept (Percent) |
For Period |
|
asln:DecreaseInUnappropriatedEarningsDueToEffectOfCorporateSurtaxRate |
| 721 |
Taxable income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 722 |
Provision for income tax |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 723 |
Withholding taxes |
Concept (Monetary) |
For Period |
Credit |
asln:WithholdingTaxes |
| 724 |
Federal income tax rate |
Concept (Percent) |
For Period |
|
asln:FederalIncomeTaxRate |
| 725 |
State income tax rate |
Concept (Percent) |
For Period |
|
asln:StateIncomeTaxRate |
| 726 |
100810 - Disclosure - Loss Per Share - Summary of Earnings Per Share (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossPerShareSummaryOfEarningsPerShareDetails |
| 727 |
Implied Table |
Table |
* |
* |
implied:Table |
| 728 |
Earnings Per Share [Abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 729 |
Basic and diluted loss per share |
Concept (Share) |
For Period |
|
ifrs-full:BasicAndDilutedEarningsLossPerShare |
| 730 |
100820 - Disclosure - Loss Per Share - Summary of Loss and Weighted Average Number of Ordinary Shares Outstanding (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossPerShareSummaryOfLossAndWeightedAverageNumberOfOrdinarySharesOutstandingDetails |
| 731 |
Implied Table |
Table |
* |
* |
implied:Table |
| 732 |
Earnings Per Share [Abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 733 |
Loss used in the computation of basic and diluted loss per share |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 734 |
Weighted-average number of ordinary shares in the computation of basic loss per share |
Concept (Shares) |
For Period |
|
ifrs-full:WeightedAverageShares |
| 735 |
100830 - Disclosure - Loss Per Share - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails |
| 736 |
Implied Table |
Table |
* |
* |
implied:Table |
| 737 |
Earnings Per Share [Abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 738 |
Anti-dilutive outstanding employee share options |
Concept (Shares) |
For Period |
|
ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares |
| 739 |
Weighted average number of convertible preference shares excluded from the computation of earnings/ loss per share |
Concept (Shares) |
For Period |
|
asln:WeightedAverageNumberOfConvertiblePreferenceSharesExcludedFromComputationOfEarningsLossPerShare |
| 740 |
Weighted Average Number of Employee Share Options Excluded from Computation of Earnings/ Loss Per Share |
Concept (Shares) |
For Period |
|
asln:WeightedAverageNumberOfEmployeeShareOptionsExcludedFromComputationOfEarningsLossPerShare |
| 741 |
100840 - Disclosure - Share-based Payment Arrangements - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsAdditionalInformationDetails |
| 742 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 743 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 744 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 745 |
Employee Share Option Plan |
Member |
|
|
asln:EmployeeShareOptionPlanMember |
| 746 |
Long Term Incentive Plans |
Member |
|
|
asln:LongTermIncentivePlanMember |
| 747 |
Long Term Incentive Plan Granted in 2017 |
Member |
|
|
asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember |
| 748 |
Long Term Incentive Plan Granted in 2018 |
Member |
|
|
asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember |
| 749 |
Vesting Period |
Axis |
|
|
asln:VestingPeriodAxis |
| 750 |
Vesting Period Member |
Member |
|
|
asln:VestingPeriodMember |
| 751 |
Vest in Thirds Each Year After the First, Second, and Third Anniversary of Award |
Member |
|
|
asln:VestInThirdsEachYearAfterTheFirstSecondAndThirdAnniversaryOfAwardMember |
| 752 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 753 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 754 |
Other Payable |
Member |
|
|
asln:OtherPayableMember |
| 755 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 756 |
Number of ordinary shares for initial public offering |
Concept (Shares) |
For Period |
|
asln:NumberOfSharesIssuedInitialPublicOffering |
| 757 |
Number of ordinary shares for subscription by employees |
Concept (Shares) |
For Period |
|
asln:NumberOfOrdinarySharesSubscriptionByEmployees |
| 758 |
Recognized compensation costs |
Concept (Monetary) |
For Period |
Credit |
asln:ShareOptionsRecognizedCompensationCosts |
| 759 |
Option granted to qualified employee |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted |
| 760 |
Share option granted expiration period |
Concept (xbrli:durationItemType) |
For Period |
|
asln:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedExpirationPeriod |
| 761 |
Description of vesting requirements for stock option |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement |
| 762 |
Decrease in exercise price for award previously granted |
Concept (Percent) |
For Period |
|
asln:DecreaseInExercisePriceForAwardPreviouslyGrantedPercentage |
| 763 |
Anti-dilutive outstanding employee share options |
Concept (Shares) |
For Period |
|
ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares |
| 764 |
Compensation costs recognized |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 765 |
Long term incentive plan bonus entitlement units granted |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement |
| 766 |
Retrospective share conversion ratio |
Concept (Percent) |
As Of |
|
asln:RetrospectiveShareConversionRatio |
| 767 |
Grant date fair value of award |
Concept (Monetary) |
For Period |
Debit |
asln:GrantDateFairValueOfAward |
| 768 |
Reporting date fair value of award |
Concept (Monetary) |
For Period |
Debit |
asln:ReportingDateFairValueOfAward |
| 769 |
Recognized total expenses |
Concept (Monetary) |
For Period |
Debit |
asln:RecognizedNetCompensationExpenses |
| 770 |
Recognized compensation liabilities, Current |
Concept (Monetary) |
For Period |
Credit |
asln:RecognizedCompensationLiabilitiesCurrent |
| 771 |
Recognized compensation liabilities, Non-current |
Concept (Monetary) |
For Period |
Credit |
asln:RecognizedCompensationLiabilitiesNonCurrent |
| 772 |
100850 - Disclosure - Share-based Payment Arrangements - Summary of Fair Value of Share Options Granted to Employees (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsSummaryOfFairValueOfShareOptionsGrantedToEmployeesDetails |
| 773 |
Implied Table |
Table |
* |
* |
implied:Table |
| 774 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract |
| 775 |
Grant-date share price (NT$) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageSharePriceShareOptionsGranted |
| 776 |
Exercise price (NT$) |
Concept (Monetary) |
For Period |
|
ifrs-full:ExercisePriceShareOptionsGranted |
| 777 |
Expected volatility |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted |
| 778 |
Expected life |
Concept (Decimal) |
For Period |
|
ifrs-full:DescriptionOfOptionLifeShareOptionsGranted |
| 779 |
Dividends yield |
Concept (Percent) |
For Period |
|
ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted |
| 780 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted |
| 781 |
Weighted-average fair value of options (NT$) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted |
| 782 |
100860 - Disclosure - Share-based Payment Arrangements - Summary of Employee Share Options (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsSummaryOfEmployeeShareOptionsDetails |
| 783 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 784 |
Ranges of exercise prices for outstanding share options [axis] |
Axis |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis |
| 785 |
Ranges of exercise prices for outstanding share options [member] |
Member |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember |
| 786 |
July 2010 to July 2016 |
Member |
|
|
asln:July2010ToJuly2016Member |
| 787 |
September 2017 |
Member |
|
|
asln:September2017Member |
| 788 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 789 |
Number of Options, Beginning of Year |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 790 |
Number of Options, Granted |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 791 |
Number of Options, Forfeited |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 792 |
Number of Options, Exercised |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 793 |
Number of Options, Ending of Year |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 794 |
Number of Options Exercisable, Ending of Year |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 795 |
Weighted-average fair value of options granted |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted |
| 796 |
Weighted- average Exercise Price, Beginning of Year |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 797 |
Weighted -average Exercise Price, Granted |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 798 |
Weighted- average Exercise Price, Forfeited |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 799 |
Weighted- average Exercise Price, Exercised |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement |
| 800 |
Weighted- average Exercise Price, End of Year |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 801 |
Weighted- average Exercise Price, Exercisable End of Year |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 802 |
100870 - Disclosure - Share-based Payment Arrangements - Summary of Outstanding Options (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsSummaryOfOutstandingOptionsDetails |
| 803 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 804 |
Ranges of exercise prices for outstanding share options [axis] |
Axis |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis |
| 805 |
Ranges of exercise prices for outstanding share options [member] |
Member |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember |
| 806 |
July 2010 |
Member |
|
|
asln:July2010Member |
| 807 |
July 2011 |
Member |
|
|
asln:July2011Member |
| 808 |
July 2012 |
Member |
|
|
asln:July2012Member |
| 809 |
July 2013 |
Member |
|
|
asln:July2013Member |
| 810 |
July 2014 |
Member |
|
|
asln:July2014Member |
| 811 |
July 2015 |
Member |
|
|
asln:July2015Member |
| 812 |
July 2016 |
Member |
|
|
asln:July2016Member |
| 813 |
September 2017 |
Member |
|
|
asln:September2017Member |
| 814 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 815 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 816 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 817 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 818 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 819 |
Weighted-average Remaining Contractual Life (Years) |
Concept (Decimal) |
As Of |
|
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions |
| 820 |
Exercise price of outstanding share options |
Concept (Monetary) |
As Of |
|
ifrs-full:ExercisePriceOfOutstandingShareOptions |
| 821 |
100880 - Disclosure - Share-based Payment Arrangements - Summary of Options Granted Priced Using Binomial Option Pricing Model (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsSummaryOfOptionsGrantedPricedUsingBinomialOptionPricingModelDetails |
| 822 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 823 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 824 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 825 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 826 |
Top of Range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 827 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 828 |
Grant-date share price (NT$) |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageSharePriceShareOptionsGranted |
| 829 |
Exercise price |
Concept (Monetary) |
For Period |
|
ifrs-full:ExercisePriceShareOptionsGranted |
| 830 |
Expected volatility |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted |
| 831 |
Expected life |
Concept (Decimal) |
For Period |
|
ifrs-full:DescriptionOfOptionLifeShareOptionsGranted |
| 832 |
Dividends yield |
Concept (Percent) |
For Period |
|
ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted |
| 833 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted |
| 834 |
100890 - Disclosure - Share-based Payment Arrangements - Summary of Long Term Incentive Plan (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureShareBasedPaymentArrangementsSummaryOfLongTermIncentivePlanDetails |
| 835 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 836 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 837 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 838 |
Long Term Incentive Plan Granted in 2017 |
Member |
|
|
asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember |
| 839 |
Long Term Incentive Plan Granted in 2018 |
Member |
|
|
asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember |
| 840 |
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 841 |
Beginning balance |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 842 |
Option granted to qualified employee |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted |
| 843 |
Awards exercised |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement |
| 844 |
Ending balance |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement |
| 845 |
Balance exercisable, end of period |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement |
| 846 |
100900 - Disclosure - Operating Lease Arrangements - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOperatingLeaseArrangementsAdditionalInformationDetails |
| 847 |
Disclosure Of Finance Lease And Operating Lease By Lessee [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable |
| 848 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 849 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 850 |
Bottom of Range |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 851 |
Top of range |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 852 |
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems |
| 853 |
Operating leases lease term |
Concept (xbrli:durationItemType) |
For Period |
|
asln:OperatingLeasesLeaseTerm |
| 854 |
100910 - Disclosure - Operating Lease Arrangements - Schedule of Future Minimum Lease Payments of Non - Cancellable Operating Lease Commitments (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureOperatingLeaseArrangementsScheduleOfFutureMinimumLeasePaymentsOfNonCancellableOperatingLeaseCommitmentsDetails |
| 855 |
Disclosure Of Finance Lease And Operating Lease By Lessee [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable |
| 856 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 857 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 858 |
Not Later than One Year |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 859 |
Later than One Year and not Later than Five Years |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember |
| 860 |
Disclosure Of Finance Lease And Operating Lease By Lessee [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems |
| 861 |
Minimum lease payments payable under non-cancellable operating lease |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease |
| 862 |
100920 - Disclosure - Financial Instruments - Fair Value of Financial Instruments Measured at Fair Value on Recurring Basis (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstrumentsFairValueOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails |
| 863 |
Disclosure Of Financial Instruments [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialInstrumentsTable |
| 864 |
Measurement [axis] |
Axis |
|
|
ifrs-full:MeasurementAxis |
| 865 |
Aggregated measurement [member] |
Member |
|
|
ifrs-full:AggregatedMeasurementMember |
| 866 |
Fair Value Measured on Recurring Basis |
Member |
|
|
ifrs-full:RecurringFairValueMeasurementMember |
| 867 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 868 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 869 |
Level 1 |
Member |
|
|
ifrs-full:Level1OfFairValueHierarchyMember |
| 870 |
Level 2 |
Member |
|
|
ifrs-full:Level2OfFairValueHierarchyMember |
| 871 |
Level 3 |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 872 |
Disclosure Of Financial Instruments [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsLineItems |
| 873 |
Financial assets at FVTPL |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossAbstract |
| 874 |
Financial assets at fair value through profit or loss (Notes 4, 7 and 15) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss |
| 875 |
Financial assets at FVTOCI |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract |
| 876 |
Investments in equity instruments at FVTOCI of unlisted companies. |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome |
| 877 |
100930 - Disclosure - Financial Instruments - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails |
| 878 |
Disclosure Of Financial Instruments [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialInstrumentsTable |
| 879 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 880 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 881 |
Level 3 |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 882 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 883 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 884 |
Foreign Currency Risk |
Member |
|
|
ifrs-full:CurrencyRiskMember |
| 885 |
Interest Rate Risk |
Member |
|
|
ifrs-full:InterestRateRiskMember |
| 886 |
Disclosure Of Financial Instruments [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsLineItems |
| 887 |
Transfer between Level 1 and 2, assets |
Concept (Monetary) |
For Period |
|
ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets |
| 888 |
Historical volatility |
Concept (Percent) |
For Period |
|
ifrs-full:HistoricalVolatilityForSharesSignificantUnobservableInputsAssets |
| 889 |
Percentage of increase or decrease on exchange rate of foreign currency |
Concept (Percent) |
For Period |
|
asln:PercentageOfIncreaseOrDecreaseOnExchangeRateOfForeignCurrency |
| 890 |
Sensitivity rate used in reporting foreign currency risk |
Concept (Percent) |
For Period |
|
asln:SensitivityAnalysisRate |
| 891 |
Percentage of increase on exchange rate of foreign currency |
Concept (Percent) |
For Period |
|
asln:PercentageOfIncreaseOnExchangeRateOfForeignCurrency |
| 892 |
Percentage of decrease on exchange rate of foreign currency |
Concept (Percent) |
For Period |
|
asln:PercentageOfDecreaseOnExchangeRateOfForeignCurrency |
| 893 |
Borrowings, interest rate basis |
Concept (Percent) |
As Of |
|
ifrs-full:BorrowingsAdjustmentToInterestRateBasis |
| 894 |
Decrease (increase) in pre-tax loss |
Concept (Monetary) |
For Period |
Credit |
asln:DecreaseIncreaseInPreTaxLossDueToHundredBasisPointIncreaseInInterestRates |
| 895 |
Concentration of credit risk |
Concept (Monetary) |
For Period |
Credit |
asln:ConcentrationOfCreditRisk |
| 896 |
100940 - Disclosure - Financial Instruments - Summary of Categories of Financial Instruments (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfCategoriesOfFinancialInstrumentsDetails |
| 897 |
Implied Table |
Table |
* |
* |
implied:Table |
| 898 |
Disclosure Of Financial Instruments [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 899 |
Financial assets |
Abstract |
|
|
ifrs-full:CategoriesOfFinancialAssetsAbstract |
| 900 |
Financial assets at FVTPL |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossAbstract |
| 901 |
Mandatorily classified as at FVTPL |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue |
| 902 |
Loans and receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:LoansAndReceivables |
| 903 |
Financial assets at amortized cost |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtAmortisedCost |
| 904 |
Financial assets at FVTOCI |
Abstract |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeAbstract |
| 905 |
Equity instruments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome |
| 906 |
Financial liabilities |
Abstract |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract |
| 907 |
Financial liabilities at amortized cost |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinancialLiabilitiesAtAmortisedCost |
| 908 |
100950 - Disclosure - Financial Instruments - Summary of Group's Significant Financial Assets and Liabilities Denominated in Foreign Currencies (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfGroupSSignificantFinancialAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails |
| 909 |
Implied Table |
Table |
* |
* |
implied:Table |
| 910 |
Disclosure Of Financial Instruments [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsAbstract |
| 911 |
Financial assets, Foreign Currencies |
Concept (Monetary) |
As Of |
Debit |
asln:FinancialAssetsExposedToForeignCurrencyRisk |
| 912 |
Financial assets, Exchange Rate |
Concept (Decimal) |
For Period |
|
asln:FinancialAssetsExchangeRate |
| 913 |
Financial assets, Carrying Amount |
Concept (Monetary) |
As Of |
Debit |
asln:FinancialAssetsCarryingValue |
| 914 |
Financial liabilities, Foreign Currencies |
Concept (Monetary) |
As Of |
Credit |
asln:FinancialLiabilitiesExposedToForeignCurrencyRisk |
| 915 |
Financial liabilities, Exchange Rate |
Concept (Decimal) |
For Period |
|
asln:FinancialLiabilitiesExchangeRate |
| 916 |
Financial Liabilities, Carrying Amount |
Concept (Monetary) |
As Of |
Credit |
asln:FinancialLiabilitiesCarryingValue |
| 917 |
100960 - Disclosure - Financial Instruments - Sensitivity Analysis of Foreign Currency Risk (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureFinancialInstrumentsSensitivityAnalysisOfForeignCurrencyRiskDetails |
| 918 |
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable |
| 919 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 920 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 921 |
Foreign Currency Risk |
Member |
|
|
ifrs-full:CurrencyRiskMember |
| 922 |
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems |
| 923 |
Impact of a 5% change in foreign exchange rates on profit or loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss |
| 924 |
100970 - Disclosure - Transactions with Related Parties - Schedule of Key Management Personnel Compensation (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureTransactionsWithRelatedPartiesScheduleOfKeyManagementPersonnelCompensationDetails |
| 925 |
Implied Table |
Table |
* |
* |
implied:Table |
| 926 |
Disclosure Of Transactions Between Related Parties [Abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract |
| 927 |
Short-term employee benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits |
| 928 |
Post-employment benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits |
| 929 |
Share-based payments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment |
| 930 |
Key management personnel compensation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensation |
| 931 |
100980 - Disclosure - Segment Information - Additional Information (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails |
| 932 |
Disclosure Of Operating Segments [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfOperatingSegmentsTable |
| 933 |
Products and services [axis] |
Axis |
|
|
ifrs-full:ProductsAndServicesAxis |
| 934 |
Products and services [member] |
Member |
|
|
ifrs-full:ProductsAndServicesMember |
| 935 |
Out-licensing |
Member |
|
|
asln:OutLicensingMember |
| 936 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 937 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 938 |
Hyundai Pharm Co., Ltd. |
Member |
|
|
asln:HyundaiPharmCoLtdMember |
| 939 |
Bristol-Myers Squibb |
Member |
|
|
asln:BristolMyersSquibbMember |
| 940 |
Disclosure Of Operating Segments [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfOperatingSegmentsLineItems |
| 941 |
Number of reportable segment |
Concept (Integer) |
For Period |
|
asln:NumberOfReportableSegment |
| 942 |
Revenue |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromContractsWithCustomers |
| 943 |
100990 - Disclosure - Segment Information - Analysis of the Group Revenue from Major Products and Services (Details) |
Network |
* |
* |
http://aslanpharma.com/20181231/taxonomy/role/DisclosureSegmentInformationAnalysisOfGroupRevenueFromMajorProductsAndServicesDetails |
| 944 |
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table] |
Table |
* |
* |
ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable |
| 945 |
Products and services [axis] |
Axis |
|
|
ifrs-full:ProductsAndServicesAxis |
| 946 |
Products and services [member] |
Member |
|
|
ifrs-full:ProductsAndServicesMember |
| 947 |
Out-licensing |
Member |
|
|
asln:OutLicensingMember |
| 948 |
Others |
Member |
|
|
asln:OtherProductsAndServicesMember |
| 949 |
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems |
| 950 |
Revenue |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromContractsWithCustomers |